Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Oversight Board Will Include VA, Other Agencies

This article was originally published in The Pink Sheet Daily

Executive Summary

The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.

You may also be interested in...



FDA's Drug Safety Oversight Board Looks To Promote Its Value

FDA's Drug Safety Oversight Board is trying to promote its value to the medical and regulatory communities by highlighting its role in addressing postmarketing safety issues

FDA's Drug Safety Oversight Board Looks To Promote Its Value

FDA's Drug Safety Oversight Board is trying to promote its value to the medical and regulatory communities by highlighting its role in addressing postmarketing safety issues

Drug Safety Oversight Efforts Paying Off, CDER’s Galson Says

The agency has held 29 advisory committee meetings on drug safety since February 2005, according to the CDER director.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel